The Ophthalmic Drugs Market is valued at USD 22.3 Bn in 2026.
The Ophthalmic Drugs Market is projected to expand at a 5% CAGR through 2033, reaching USD 30.6 Bn.
The market is driven by the rising prevalence of eye disorders, growing geriatric population, and increasing development of advanced ophthalmic therapies.
Asia Pacific is the dominant regional market for Ophthalmic Drugs due to its large patient population and increasing burden of vision-related disorders.
Alcon, Novartis AG, Bausch Health Companies, Inc., AbbVie, Inc. (Allergan), and Pfizer, Inc. are among the leading players in the Ophthalmic Drugs Market.